> News > Haya Therapeutics passes Venture Kick stage 2
Haya Therapeutics passes Venture Kick stage 2
Congratulations to HAYA Therapeutics selected by the jury to receive CHF 20,000 from Venture Kick
HAYA Therapeutics (a member of StartLab, Biopôle’s life science incubator) is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. The startup aims to be the first company and world leader in translating long noncoding RNA discoveries into breakthrough bench-to-bedside tools to monitor and treat heart failure patients.